Mumbai, Feb. 24 -- Eris Lifesciences has tied up with Hyderabad-based Natco Pharma to commercialise semaglutide, ahead of the blockbuster weight-loss drug's patent expiry.

The partnership comes on the heels of Natco receiving regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) on 14 February to manufacture generic semaglutide for the Indian market. This paves the way for a launch expected in March 2026, Eris said in a statement on Tuesday.

The collaboration will leverage Eris's commercial presence in the diabetes segment and Natco's manufacturing and regulatory prowess in complex formulations, the company said.

The product will target type 2 diabetes management, aligning with unmet needs in India's expandin...